EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mannose-engineered nanoparticles for site-specific delivery of fluconazole to treat cutaneous leishmaniasis

Zahra A Alamri, Noha T Zelai, Amaal H Hassan

PeerJ · 14.07.2026 · 14 · e21566

DOI: 10.7717/peerj.21566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, online erschienen am 14.07.2026. Verfasst von Zahra A Alamri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Faculty of Science, King Abdul Aziz University, Jeddah, Makkah, Saudi Arabia. Hauptthemen laut MEDLINE: Fluconazole, Leishmaniasis, Cutaneous, Nanoparticles, Mannose. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: WAQF and the Deanship of Scientific Research (DSR) at King Abdulaziz University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cutaneous leishmaniasis (CL) is a skin disease that affects people living in arid and semi-arid regions. The main limitation in current management is that treatment primarily targets the cutaneous lesions, while immune-mediated effects is often not addressed. In addition, there is a need for new treatment with minimized side effects. Fluconazole (FCZ) has been used for treating CL before.

Methods

In the present study, FCZ was entrapped in a chitosan (CS) nanopolymer and conjugated with mannose (MNS) to target amastigotes inside macrophages in CL-infected Balb/c male mice. Parasites were detected using Enzyme-Linked Immunosorbent Assay (ELISA) and Polymerase chain reaction (PCR).

Results

The resulting FCZ CS MNS NPs nanoparticles exhibited small size (71.96 ± 11.4 nm) good stability (31.2 ± 0.173 nm), release over an extended period, and long-term bioavailability. The FCZ CS MNS nanoparticle-treated mice showed negative PCR results and low IgG levels compared to the positive control ( P < 0.0001). This indicated potent targeting of infected macrophages that affects the parasite before it replicates and exits into the bloodstream. This study provides evidence for the effect of an antileishmanial formulation. Additional toxicity studies should be performed on this formulation before it undergoes clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluconazoleLeishmaniasis, CutaneousNanoparticlesMannoseAntiprotozoal AgentsAnimalsMaleMiceMice, Inbred BALB CChitosanMacrophages

Stichwörter der Autor:innen

ChitosanCutaneous leishmaniasisFluconazoleMannoseNanoparticles

Substanzen

FluconazoleMannoseChitosanAntiprotozoal Agents

Autor:innen und Institutionen

  • Department of Biological Sciences, Faculty of Science, King Abdul Aziz University, Jeddah, Makkah, Saudi Arabia.
  • Department of Biology, Faculty of Science, King Khalid University, Abha, Saudi Arabia.

Förderung

  • WAQF and the Deanship of Scientific Research (DSR) at King Abdulaziz University

Zitieren

APA

Alamri, Z. A., Zelai, N. T., & Hassan, A. H. (2026). Mannose-engineered nanoparticles for site-specific delivery of fluconazole to treat cutaneous leishmaniasis. PeerJ, 14, e21566. https://doi.org/10.7717/peerj.21566

Vancouver

Alamri ZA, Zelai NT, Hassan AH. Mannose-engineered nanoparticles for site-specific delivery of fluconazole to treat cutaneous leishmaniasis. PeerJ. 2026;14:e21566. doi:10.7717/peerj.21566

BibTeX
@article{Alamri2026,
  author = {Alamri, Zahra A and Zelai, Noha T and Hassan, Amaal H},
  title = {Mannose-engineered nanoparticles for site-specific delivery of fluconazole to treat cutaneous leishmaniasis},
  journal = {PeerJ},
  year = {2026},
  volume = {14},
  pages = {e21566},
  doi = {10.7717/peerj.21566}
}
Kostenlos starten →